Evidence map›Paper›PMID 38184681›Full record

ArticleNPJ vaccines2024

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Francisco J Martinez, Michael White, Micheline Guillotte-Blisnick, Christèle Huon, Alix Boucharlat, Fabrice Agou, Patrick England, Jean Popovici, Mimi M Hou, Sarah E Silk and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Accessing invasion-competentScience advances · 2026
    Article
  2. Review
  3. Article
  4. Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024
    Review
  5. Article
  6. Frontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Francisco J MartinezUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-2827-0497
Michael WhiteInfectious Disease Epidemiology and Analytics G5 Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Micheline Guillotte-BlisnickUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.
Christèle HuonUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France.
Alix BoucharlatChemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France.
Fabrice AgouChemogenomic and Biological Screening Core Facility, C2RT, Institut Pasteur, Université Paris Cité, CNRS UMR 3523, Paris, France.
Patrick EnglandMolecular Biophysics Facility, CNRS UMR 3528, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0001-6410-5918
Jean PopoviciMalaria Reasearch Unit, Institut Pasteur du Cambodge, Pnom Penh, Cambodia.
Mimi M HouDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.ORCID http://orcid.org/0000-0002-8517-9147
Sarah E SilkDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Jordan R BarrettDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Carolyn M NielsenDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Jenny M ReimerNovavax AB, Kungsgatan 109, SE-753 18, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-0287-4575
Paushali MukherjeeMulti-Vaccines Development Program, ICGEB Campus, New Delhi, India.
Virander S ChauhanInternational Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.ORCID http://orcid.org/0000-0001-9875-9549
Angela M MinassianDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Simon J DraperDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.ORCID http://orcid.org/0000-0002-9415-1357
Chetan E ChitnisUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, Paris, France. chetan.chitnis@pasteur.fr.
University of Oxford · GBInstitut Pasteur · FRCentre National de la Recherche Scientifique · FRInternational Centre for Genetic Engineering and Biotechnology · INInstitut Pasteur du Cambodge · KHNovavax (Sweden) · SE

Funding

Comprehensive characterization of the genetic factors and the host immune response associated to protection from clinical Plasmodium vivax malariaR01AI175134 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI TINEKE CANTAERT, Jean POPOVICI · 2023 to 2026
$2.3M
Medical Research Council G1100086NIAID NIH HHS R01 AI175134Wellcome Trust
6 · The paper itself

Abstract

The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed dosing regimen with recombinant PvDBPII SalI variant formulated with adjuvant Matrix-M

Identifiers

PMID38184681
PMCPMC10771494
OpenAlexW4390640216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.